Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Non-Current Assets: 2019-2024

Historic Non-Current Assets for BridgeBio Pharma (BBIO) over the last 6 years, with Dec 2024 value amounting to $198.6 million.

  • BridgeBio Pharma's Non-Current Assets fell 27.92% to $158.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $158.9 million, marking a year-over-year decrease of 27.92%. This contributed to the annual value of $198.6 million for FY2024, which is 188.78% up from last year.
  • Latest data reveals that BridgeBio Pharma reported Non-Current Assets of $198.6 million as of FY2024, which was up 188.78% from $68.8 million recorded in FY2023.
  • BridgeBio Pharma's Non-Current Assets' 5-year high stood at $198.6 million during FY2024, with a 5-year trough of $60.8 million in FY2020.
  • Its 3-year average for Non-Current Assets is $113.9 million, with a median of $74.2 million in 2022.
  • Its Non-Current Assets has fluctuated over the past 5 years, first slumped by 40.14% in 2022, then skyrocketed by 188.78% in 2024.
  • BridgeBio Pharma's Non-Current Assets (Yearly) stood at $60.8 million in 2020, then skyrocketed by 103.96% to $123.9 million in 2021, then crashed by 40.14% to $74.2 million in 2022, then declined by 7.27% to $68.8 million in 2023, then spiked by 188.78% to $198.6 million in 2024.